Paediatric Haematology and Acute Lymphoblastic Leukaemia
Research activity includes acute lymphoblastic leukaemia in children and adolescents, with interest in high-risk B-cell precursor ALL, genetic risk stratification, and treatment response-guided care. The sponsor is involved in studies addressing minimal residual disease and relapsed or refractory disease management.
- Childhood acute lymphoblastic leukaemia
- High-risk paediatric oncology
- Minimal residual disease
- Immunotherapy in leukaemia
Therapeutic interest extends to proteasome inhibition, antibody-based immunotherapy, and intrathecal methotrexate within collaborative paediatric cancer care.
Neuro-Oncology and Glioblastoma Multiforme
The sponsor supports research in glioblastoma multiforme, with focus on newly diagnosed disease and treatment strategies integrated with standard chemo-radiotherapy. Clinical interest centres on tumour control, tolerability, and outcomes in aggressive primary brain tumours.
- Glioblastoma multiforme
- Primary brain tumours
- Checkpoint inhibition
- Neoadjuvant and adjuvant therapy
Key therapeutic domains include pembrolizumab, immune checkpoint blockade, and multimodal treatment alongside the Stupp protocol.
Cardiorenal Medicine and Atrial Fibrillation
Clinical research also addresses atrial fibrillation in the setting of advanced chronic kidney disease stage 5, including patients receiving dialysis. The sponsor’s interest lies in reducing thromboembolic risk while managing bleeding concerns in complex cardiovascular and renal disease.
- Atrial fibrillation
- Chronic kidney disease stage 5
- Stroke prophylaxis
- Dialysis-associated care
Therapeutic focus includes oral anticoagulation, apixaban, and prevention of ischaemic stroke and systemic embolism in high-risk cardiorenal populations.
